{"name":"Artcline GmbH","slug":"artcline-gmbh","ticker":"","exchange":"","domain":"","description":"Artcline GmbH is a biotechnology company focused on developing innovative treatments in the early stages of clinical development. The company's lead product, ARTICE, is currently in Phase 2 trials. Limited financial and operational data is available.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARTICE","genericName":"ARTICE","slug":"artice","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"}]}],"pipeline":[{"name":"ARTICE","genericName":"ARTICE","slug":"artice","phase":"phase_2","mechanism":"ARTICE is a small molecule that targets the underlying cause of a specific disease.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}